Analysis of potential barriers for non-PrEP users among MSM in Germany
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background
Daily oral pre-exposure prophylaxis (PrEP) provides effective protection against HIV. Since September 2019, the costs of PrEP have been reimbursed by statutory health insurance in Germany. While a considerable fraction of PrEP-eligible individuals receives PrEP, coverage is inhomogeneous across Germany. This study aims to identify potential barriers associated with PrEP non-use.
Methods
Based on the PrApp online cross-sectional study, we analyzed 1,027 PrEP users and 431 non-PrEP users. A PrEP indication was assumed for cis-MSM with an STI diagnosis (12 months), ≥ 2 sex partners or sexualized drug use (6 months). Characteristics between PrEP users and PrEP non-users were compared descriptively and using multivariable logistic regression.
Results
Non-PrEP users were more likely to be aged 18-29 years old ( P < 0.05) and to use drugs during sex ( P < 0.01). The highest PrEP prescriber density ( P < 0.01) was associated with PrEP use. Fear of side effects (54.5%) was the most common barrier. Persons with sexualized drug use were more likely to report daily PrEP use as a barrier (34.3% vs. 16.9%, P < 0.01, adjusted P < 0.05).
Conclusions
Our analyses indicated structural barriers to PrEP use in federal states with a low HIV-specialists density. For those engaging in sexualized drug use, daily PrEP uptake could potentially be overcome by long-acting PrEP.
